Intellia Therapeutics Inc. (NASDAQ:NTLA) and Axsome Therapeutics Inc. (NASDAQ:AXSM) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intellia Therapeutics Inc.||30.43M||24.19||85.34M||-2.16||0.00|
|Axsome Therapeutics Inc.||N/A||0.00||30.97M||-1.13||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of Intellia Therapeutics Inc. and Axsome Therapeutics Inc.
Table 2 shows us the return on assets, net margins and return on equity of both businesses.
|Net Margins||Return on Equity||Return on Assets|
|Intellia Therapeutics Inc.||-280.45%||-30.6%||-25%|
|Axsome Therapeutics Inc.||0.00%||-310.9%||-113.7%|
Intellia Therapeutics Inc. has a Current Ratio of 8 and a Quick Ratio of 8. Competitively, Axsome Therapeutics Inc.’s Current Ratio is 1.5 and has 1.5 Quick Ratio. Intellia Therapeutics Inc.’s better ability to pay short and long-term obligations than Axsome Therapeutics Inc.
Intellia Therapeutics Inc. and Axsome Therapeutics Inc. Recommendations and Ratings are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intellia Therapeutics Inc.||0||0||0||0.00|
|Axsome Therapeutics Inc.||0||0||1||3.00|
Competitively the average target price of Axsome Therapeutics Inc. is $25, which is potential 53.00% upside.
Institutional & Insider Ownership
Institutional investors owned 74.6% of Intellia Therapeutics Inc. shares and 12.9% of Axsome Therapeutics Inc. shares. About 24.01% of Intellia Therapeutics Inc.’s share are owned by insiders. Comparatively, Axsome Therapeutics Inc. has 30.4% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intellia Therapeutics Inc.||15.53%||17.33%||-2.93%||-44.98%||-34.45%||21.54%|
|Axsome Therapeutics Inc.||-12.24%||-3.46%||154.72%||145.45%||217.65%||187.23%|
For the past year Intellia Therapeutics Inc. was less bullish than Axsome Therapeutics Inc.
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.